PFG
SNDX icon

PAX Financial Group’s Syndax Pharmaceuticals SNDX Stock Holding History

PAX Financial Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,458
Closed -$575K – 237
2023
Q2 		$575K Buy
27,458
+3,750
+16% +$78.1K 0.13% 144
2023
Q1 		$501K Buy
+23,708
New +$590K 0.12% 149

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

PAX Financial Group's SNDX Position: Q3 2023 in Review

PAX Financial Group sold out of Syndax Pharmaceuticals (SNDX) in Q3 2023, closing a stake of 27,458 shares — an estimated $575K sold.

PAX Financial Group first reported a position in SNDX in Q1 2023 and held it in 2 quarters. The position peaked at $575K in Q2 2023. 175 funds tracked by Wall St. Rank hold SNDX as of Q3 2023.

  • PAX Financial Group reported no remaining Syndax Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • PAX Financial Group sold 27,458 Syndax Pharmaceuticals shares in Q3 2023, an estimated $575K.
  • PAX Financial Group first reported a position in Syndax Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • PAX Financial Group's Syndax Pharmaceuticals position peaked at $575K in Q2 2023.
  • 175 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2023.

Based on PAX Financial Group's 13F filing for Q3 2023, filed 13 Nov 2023.